|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute on Aging (NIA) |
| Information provided by: | National Institute on Aging (NIA) |
| ClinicalTrials.gov Identifier: | NCT00094939 |
Purpose
The goal of this project is to develop an early diagnostic test for Alzheimer's disease (AD) by monitoring loss of neurons and brain size reductions over a period of five years.
| Condition | Phase |
|
Alzheimer Disease Dementia |
Phase II |
| Genetics Home Reference related topics: | Alzheimer disease |
| MedlinePlus related topics: | Alzheimer's Disease Dementia |
| Study Type: | Observational |
| Study Design: | Screening, Longitudinal, Case Control, Prospective Study |
| Official Title: | Predictors of Cognitive Decline in Normal Aging |
| Estimated Enrollment: | 170 |
| Study Start Date: | September 2003 |
| Estimated Study Completion Date: | August 2008 |
Studies of normal aging and mild cognitive impairment (MCI) show that loss of neurons and reduction in size of the hippocampal part of the brain predict a person's conversion from MCI to Alzheimer's disease (AD). Increases in tangle-related abnormal tau proteins, specifically P-tau231, also appear to be related.
This study will collect neuropsychological data, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) from volunteer participants to measure the relationship between changes in brain volume, CSF levels, and memory performance.
From the data researchers hope to develop an early diagnostic test for AD.
The study will include 170 participants between the ages of 60 and 80 years, some normal, some with MCI, some with mild AD, and some with frontotemporal dementia. After initial screening of volunteers, the researchers will give participants a complete baseline exam and 24-month follow-up exams over a period of five years.
Eligibility
| Ages Eligible for Study: | 60 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Kenneth E. Rich | 212-263-7563 | kenneth.rich@med.nyu.edu |
| United States, New York | |||||
| Center for Brain Health, Silberstein Institute, New York University School of Medicine | Recruiting | ||||
| New York City, New York, United States, 10016 | |||||
| Contact: Kenneth E. Rich 212-263-7563 kenneth.rich@med.nyu.edu | |||||
| Principal Investigator: | Mony J. de Leon, Ed.D. | Center for Brain Health, Silberstein Institute |
More Information
| Study ID Numbers: | IA0056, R01 AG12101 |
| First Received: | October 28, 2004 |
| Last Updated: | July 11, 2007 |
| ClinicalTrials.gov Identifier: | NCT00094939 |
| Health Authority: | United States: Federal Government |
|
|
|
|